Purchase this article with an account.
Hidenaga KOBASHI, Lokendra Bengani, Amy E. Ross, Hualei Zhai, Sharad Mittal, Sunil Chauhan, Daniel S. Kohane, Joseph B Ciolino; Inhibition of Corneal Neovascularization by Dexamethasone-Eluting Contact Lenses in a Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1000.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effects of dexamethasone-eluting contact lenses (D-lenses) on experimentally induced corneal neovascularization (CNV) and to compare the efficacy to that of the current mainstay of treatment, which is the frequent use of steroid eye drops.
CNV was induced by placing 7-0 silk sutures along the superior and inferior corneas of the right eye of New Zealand white rabbits, which were then exposed to one of the following regimens for one week: 1) no Treatment, 2) topical dexamethasone sodium phosphate drops (0.1 %, 8 drops a day), 3) D-lenses, 4) Contact lenses without dexamethasone (n = 6 per group). Two masked observers measured the area of CNV (mm2) from slit lamp photographs taken on day 7. Corneal inflammation was assessed on day 7 by analyzing CD45+ cell (leukocyte) frequencies in corneal tissue using flow cytometry.
CNV area (mm2) was less for D-Lens (4.0 ± 2.2) compared to no treatment (15.0 ± 3.2, p < 0.001) or contact lenses without dexamethasone (17.6 ± 2.6, p < 0.001), but not significantly different from hourly dexamethasone drops (3.4 ± 2.8, p=0.966). The frequencies of CD45+ cells in corneal tissues were significantly lower in D-Lens (5.0 ± 4.5) group compared to no treatment (14.8 ± 4.1, p < 0.001) or contact lens without dexamethasone (10.5 ± 4.0, p = 0.023) group, but were not different from dexamethasone hourly drop group (4.8 ± 2.7, p=0.942).
Dexamethasone-eluting contact lens effectively inhibited CNV and corneal inflammation, similar to the efficacy of hourly-administred dexamethasone eye drops. Contact lens drug delivery may be an option for the prevention of post-keratoplasty rejection and a platform for ocular drug delivery.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only